Yale Cancer Center | Strategic Alliance Partners

Yale Cancer Center (YCC) is one of only 56 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.

Latest from Yale Cancer Center

Five Under 5: Top Oncology Videos for the Week of 5/4

May 11, 2025

Article

The top 5 OncLive videos of the week cover insights in myelodysplastic syndrome, lung cancer, hepatocellular carcinoma, colorectal cancer, and ovarian cancer.

Dr Zeidan on the Evaluation of Immunotherapy and Other Novel Therapies in MDS

May 08, 2025

Video

Amer Zeidan, MBBS, discusses completed and ongoing research evaluating immunotherapy and other novel agents in patients with myelodysplastic syndromes.

Dr Cecchini on the Efficacy of Neoadjuvant Chemotherapy in CRC Liver Metastases

April 29, 2025

Video

Michael Cecchini, MD, discusses the effects of neoadjuvant chemotherapy on tumor-infiltrating lymphocyte levels in colorectal cancer with liver metastases.

Radioligand Therapy Advances Represent the Future of mCRPC Treatment: With Daniel P. Petrylak, MD

April 24, 2025

Podcast

Daniel P. Petrylak, MD, discusses the role of Lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.

Deintensification of Treatment Modalities Is Crucial to Consider in Head and Neck Cancer

April 24, 2025

Article

Zafar Sayed, MD, explains advances in surgical head and neck cancer approaches, including the use of transoral robotic surgery.

Study Reveals Subgroups of Patients With RCC Who May Have Durable Responses to Immunotherapy: With David A. Braun, MD, PhD

March 27, 2025

Podcast

Dr Braun discusses molecular factors that contribute to exceptional immune checkpoint inhibition responses among patients with renal cell carcinoma.

Novel Curriculum Aims to Address Burnout and Foster Wellness Among Fellows

March 25, 2025

Article

Thejal Srikumar, MD, MPH, discusses the Yale School of Medicine's unique approach to offering fellows a space to address professional burnout.

Dr Oh on the Development of Targeted Therapies in Prostate Cancer

February 17, 2025

Video

William K. Oh, MD, highlights the evolution of targeted therapy for prostate cancer treatment, including antibody-drug conjugates and bispecific antibodies.

Oncology Experts Preview Top Abstracts From 2025 ASCO GU

February 12, 2025

Article

Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.

Yale Medicine Takes Top Spots in National, State Rankings

February 06, 2025

Article

Yale Medicine was ranked third in the nation for physician practices, an annual designation by Castle Connolly.

The Potential of Oral HMAs in MDS

February 03, 2025

Video

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the potential for the use of oral HMAs in MDS.

Where Imetelstat Fits Into the Paradigm for Transfusion-Dependent Anemia in MDS

February 03, 2025

Video

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the implications of the FDA approval of imetelstat for transfusion-dependent anemia in MDS.

Other Potential Roles for Luspatercept in MDS And Beyond

February 03, 2025

Video

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss other potential roles for luspatercept in MDS and beyond.

Long-Term Transfusion Independence Data for Luspatercept vs ESAs in Lower-Risk MDS

February 03, 2025

Video

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss long-term transfusion independence data for luspatercept in MDS.

Optimal Goals for Anemia and Transfusion Independence in MDS

February 03, 2025

Video

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on treatment goals for anemia and transfusion independence in MDS.

Clinical Implications of FDA Approval of Luspatercept for Anemia in ESA-Naive Lower-Risk MDS

February 03, 2025

Video

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on the FDA approval of luspatercept in ESA-naive lower-risk MDS.

The Importance of Treating Anemia in MDS

February 03, 2025

Video

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the importance of treating anemia in myelodysplastic syndrome.

2024 FDA Approvals Highlight New Treatment Considerations in HR+ Breast Cancer

January 22, 2025

Article

Eric Winer, MD, discusses the significance of 2 FDA approvals for HR-positive, HER2-negative breast cancer and emerging novel breast cancer treatments.

Quantitative IHC Assays May Bridge Gaps in Breast Cancer IHC Test Concordance

January 21, 2025

Article

David Rimm, MD, PhD, discusses pathology limitations that have been exacerbated by the current lineup of breast cancer IHC tests.

Emerging HER2-Directed Agents May Address Resistance to SOC Regimens in Pretreated HER2+ Breast Cancer

January 14, 2025

Article

Ian Krop, MD, PhD, spotlights emerging HER2-directed agents of interest for pretreated patients with HER2-positive breast cancer.